|
Claims  |
|
|
We claim:
1. A device suitable for use in the intermittent or even continuous
administration of a therapeutic substance such as insulin, which device
comprises:
a cannula of biocompatible plastics material for indwelling in a patient
and defining a cannula through-passage;
a hub defining a hub through-passage; and
a separator means, the respective cannula and hub through-passages being
isolatable from each other by said separator means, said separator means
being disposed between the proximal end of the cannula and the proximal
end of the hub and the hub being operatively connected with the cannula,
the respective said through-passages and said separator means serving, in
use, to permit a needle to penetrate the hub and cannula through them and,
when necessary, to extend beyond the distal end of the cannula, the
through-passage of the hub also serving, in use, to guide an injection
needle passed therethrough so that the needle thus guided will pass
through the separator means at a position where the needle is aligned with
the through-passage of the cannula;
said hub being a two-component hub assembly comprising a first hub
component and a second hub component, and the separator means being
located between the two components of the hub;
said first hub-component comprising a body defining an axial bore which at
its distal end is adapted to receive the proximal end of the cannula,
whereby the through-passage of the cannula is positioned in communication
with the bore, and at its other end a socket communicating with the bore
and adapted to receive a plug-portion of said second hub-component also
comprising a body defining an axial bore, the bores in the respective
first and second hub-components being aligned to communicate with each
other and together defining said hub through-passage in the hub-assembly.
2. A device according to claim 1, including overpenetration-restraining
means for preventing the tip of a hypodermic syringe injection needle from
passing much beyond the separator means.
3. A device according to claim 2, wherein the overpenetration-restraining
means are provided by arranging that the overall penetrable length of the
through-passage in the hub is slightly shorter than a standard hypodermic
needle to be used in conjunction with the device.
4. A device according to claim 1, having a dead-space volume of about 0.75
units of U-100 insulin or below.
5. A device according to claim 4, wherein said dead-space volume is from
about 0.5 to about 0.3 units of U-100 insulin.
6. A device according to claim 1 wherein the mouth of the through-passage
in the hub most remote from the cannula is shaped such that the passage
has a conical or funnelled entrance zone.
7. A device according to claim 1 which includes a penetrable cap disposed
at the proximal end of the hub, covering the entrance of the hub
through-passage to prevent ingress of dirt or other undesirable material
when an injection needle is not inserted therein.
8. A device according to claim 1 wherein the cannula comprises a flexible
synthetic plastics material.
9. A device according to claim 8, wherein the cannula comprises
medical-implant grade synthetic polymer.
10. A device according to claim 8 wherein the hub also comprises a
biocompatable material suitable for use with drugs and next to skin.
11. A device according to claim 1, wherein the separator means is a
self-sealing diaphragm sandwiched between the two hub-components.
12. A device according to claim 11, wherein the self-sealing diaphragm
comprises a natural rubber, a silicone rubber or another self-sealing
elastomeric polymer.
13. A device according to claim 1, wherein the first hub-component body
includes an elongated nose portion at it distal end within which a portion
of the proximal end of the cannula can be accommodated.
14. A device according to claim 13, wherein the bore in the first hub
component is of greater diameter than the diameter of the through-passage
where it accommodates the tip of the proximal end of the cannula, thus
providing an annular abutment for the tip of the proximal end of the
cannula to permit securing of the cannula to the hub.
15. A device according to claim 1, wherein the cannula is shaped at its
distal tip so that the cannula tapers towards and close to the projecting
tip of a puncture needle, when the latter is disposed within the device,
to enable the device to penetrate the skin, and so that front edges
thereof are relatively smooth.
16. A device according to claim 1, which includes a self-adhesive support
portion on the hub to enable the hub to adhere to the patient's skin when
pressed thereagainst.
17. A device according to claim 1 which includes a hub having means to
accommodate a supply line lock fitment.
18. A device according to claim 17, wherein the hub is formed with one or
more Luer lock lugs or with means to accommodate a Luer lock adaptor.
19. A device according to claim 1, wherein the first and attend
hub-components are arranged so that the plug-portion of the second
hub-component includes an annular flange, and the plug-portion mates with
the socket in the first hub-component in such a manner that an annular
locking groove is formed between the flange and the end of the first
hub-component adjacent the flange.
20. A device according to claim 1, in combination with a skin puncture
needle.
21. A device according to claim 1 combination with a supply line
arrangement operatively connected with said needle.
22. A device suitable for use in the intermittent or even continuous
administration of a therapeutic substance such as insulin, which device
comprises:
a cannula of biocompatible plastics material for indwelling in a patient
and defining a cannula through-passage;
a hub defining a hub through-passage; and
a separator means, the respective cannula and hub through-passages being
isolatable from each other by said separator means, said separator means
being disposed between the proximal end of the cannula and the proximal
end of the hub and the hub being operatively connected with the cannula,
the respective said through-passages and said separator means serving, in
use, to permit a needle to penetrate the hub and cannula through them and,
when necessary, to extend beyond the distal end of the cannula, the
through-passage of the hub also serving, in use, to guide an injection
needle passed therethrough so that the needle thus guided will pass
through the separator means at a position where the needle is aligned with
the through-passage of the cannula;
a skin puncture needle;
a supply line arrangement operatively connected with said needle;
the supply line arrangement including mounted on an end portion of a supply
line, said needle, being adapted to penetrate the separator means of the
device and a pivotal clip engageable with the hub of the device to lock
together the device and the supply line. |
|
|
|
|
Claims  |
|
|
Description  |
|
|
The present invention relates to a device suitable for the administration
of a therapeutic substance, for example insulin, especially but not
necessarily on an intermittent basis.
Insulin-dependent diabetics rely upon subcutaneous doses of insulin
administered, and usually self-administered, by means of a syringe and a
hypodermic needle. This involves the psychological trauma of
self-injection, as well as the inconvenience of the overall procedure.
Insulin may also be delivered by electrical, mechanical or hand-operated
pumps.
Alternatively, it is also possible to use an indwelling needle through
which insulin may be administered. The facility to give injections via
indwelling needles is not new (see, for example U.S. Pat. No. 4,568,335),
but there are two problems with such indwelling needles as currently
available. First, the needles are sharp and made of rigid steel, which can
be painful in situ; and secondly, in the injection port attached to the
needle there is a large "dead-space", that is the space in the device
within which insulin will be withheld instead of being expressed to the
patient, which gives rise to problems not merely the problems involved in
taking account of the dead-space when calculating doses of insulin, but
also the further problems which arise when injecting more than one species
of insulin. Furthermore, the kind of needles employed for this purpose and
their associated apparatus are often designed for giving large volumes of
solution, or for sampling blood. Still further, as shown for example in
the above-mentioned United States Patent Specification the connection
between the feed syringe or the like and the needle cannot be broken,
since there is no seal in or associated with the needle itself.
In an effort to eliminate dead-space problems, there has been marketed in
the U.K. a so-called "button" infuser, which is said to have a nominal
"dead-space" volume of less than 0.33 units of U-100 insulin. However,
that "button" infuser again has a steel needle, leading to discomfort;
and, while this device is self sealing, it is difficult to ensure that the
intermittent injection needle (which has to be inserted into the
indwelling needle) is always during its insertion accurately placed, so
that first it does not over-penetrate and engage the plastics material in
the hub of the indwelling needle, and so that secondly it does not
under-penetrate and fail to enter the indwelling needle lumen beyond the
self-sealing diaphragm. The cause of this difficulty is that in this known
"button" infuser the self-sealing diaphragm takes the form of a relatively
thick seal at the mouth of the device; or in other words, the seal is
positioned so that it must be pierced before the device can be entered,
and this in practice causes entry problems. Thus, for example, where the
device is worn say on the patient' s abdomen, the patient must look down
and, with a fairly restricted view of the mouth of the device, attempt to
penetrate a relatively thick seal, without either under-penetrating or
over-penetrating as described above.
We have now found surprisingly that the disadvantages of the known "button"
infuser can be avoided, while at the same time still having a dead space
of only relatively small volume, by disposing the seal in the body of a
cannula hub, the seal being disposed not only adjacent the hub-end
connected to the cannula, but also at the distal end of a needle guide
passage through the hub, which ensures correct alignment of the injection
needle as it passes through the hub and penetrates the seal.
Accordingly, the present invention provides a device suitable for use in
the intermittent or even continuous administration of a therapeutic
substance (such as insulin), which device comprises a cannula of
biocompatible plastics material for indwelling in a patient and defining a
through-passage (lumen), together with a hub also defining a
through-passage, the respective cannula and hub passages being isolatable
from each other by separator means (such as a self-sealing diaphragm)
disposed between them, the arrangement of the respective passages
themselves and together with said separator means being such as to permit
a needle to penetrate the hub and cannula through them and, when
necessary, to extend beyond the distal end of the cannula, the
through-passage of the hub also being so constructed and arranged as to
guide an injection needle passed therethrough so that the needle thus
guided will pass through the separator means at a position where the
needle is aligned with the through passage of the cannula.
In use the device of the invention can be positioned with its cannula
implanted subcutaneously in the patient by means of a skin-puncture needle
which may be already disposed in the device or inserted therein when
required, and which extends beyond the distal end of the cannula Once the
cannula of the device has thus been implanted, the skin-puncture needle is
withdrawn, and the device can be taped in place to be left in situ for use
in the administration of one or more doses of insulin or the like as
necessary. For example, but fairly typically, the device may be left in
situ for four days, and over that period of time up to 16 doses or more of
insulin may be injected through the device, effectively involving only the
single initial skin puncture.
For the purpose of giving an injection of insulin or the like the needle of
a hypodermic syringe containing the insulin or the like is passed along
the through-passage in the hub. Once it reaches the end of that passage,
the needle passes through the separator means. Preferably, its movement
past a position where its tip is just beyond the separator means is then
prevented by including in the device of the invention over
penetration-restraining means. Conveniently, this can be accomplished by
arranging the hub so that the overall penetrable length of the
through-passage therein is just a little shorter than a standard
hypodermic needle. For example, one typical standard hypodermic needle for
insulin injection is an 11 mm needle.
In the device of the invention, the through passage in the cannula and the
through-passage in the hub are separated by separator means. While in
theory any suitable separator means could be employed, for example
mechanical separator means such as a valve, it is in practice generally
preferred to employ a self sealing diaphragm. Such a diaphragm may
comprise a variety of self-sealing elastomeric materials, for example,
natural rubber, silicone rubber or a suitable grade of any other
elastomeric polymer.
By providing a hub having a through-passage and which includes a
self-sealing diaphragm or like separator means at the distal end of the
passage adjacent the entrance to the cannula, accurate placement of the
injection needle can be accomplished. Thus, in the first place accurate
alignment between the needle and the cannula lumen can be accomplished by
the arrangement of the through-passage in the hub; and secondly, the
length of the hub can be chosen so that the desired amount of penetration
of the diaphragm or the like is achieved, but no more.
In the device of the invention, the nominal "deadspace" volume generally
may be any chosen volume of about 0.75 units of U-100 insulin or below.
Thus, while in theory larger "dead-space" volumes may be chosen--since
notionally at least the self-sealing diaphragm or the like always holds a
small volume of insulin in the cannula passage beyond the diaphragm
seal--nevertheless because "dead-space" volumes of about 0.75 units of
U-100 insulin or below are easily achieved with the device of the
invention, as described herein, and because the smaller the "dead-space"
volume the more flexible the device can be in terms of the ability to
avoid the need to flush when changing insulin dosage or species,
"deadspace" volumes below the figure stated above are generally preferred.
More preferably, however, the "dead-space" volume should be in the range
of from about 0.5 to about 0.3 units of U-100 insulin.
Furthermore, in the device of the invention the mouth of the
through-passage in the hub most remote from the cannula is desirably so
shaped that the passage has a conical or funnelled entrance zone. By
providing a conical or funnelled entrance zone, penetration of the mouth
of the through-passage in the hub by the hypodermic needle is facilitated
even when the cannula is positioned in situ, and even though the patient's
view of the mouth of the through-passage may be restricted. Also, the
conical or funnelled entrance zone provides a guide portion permitting
easy penetration of the mouth of the through-passage even where the
passage mouth is covered, as is preferred, by a self-sealing cap or the
like, as described below. It will be appreciated that ingress of dirt or
other undesirable material into the device can be avoided if the hub
includes means such as a cap to prevent such ingress.
As indicated above, the device of the invention generally may remain in
situ for a period in the region of about 4 days, with a typical period
being say from about 2 to about 5 days. Since the device includes a
cannula of biocompatible plastics material, irritation generally is kept
to a minimum, and the plastics cannula is thus less noticeable to the
wearer once placed in situ than a corresponding steel cannula. Moreover,
the patient can feel confident once the device is in situ that the
next-following series of injections (say 16 or more further injections)
can be accomplished without trauma and, furthermore, that no insulin loss
will occur. That is because the injection needle is securely guided to
proper placement in the injection port, and generally cannot be
misdirected or misplaced.
Preferably, the cannula comprises a flexible synthetic plastics material,
generally formed of one or more synthetic polymers, for example, of one or
more fluorocarbons such as "Teflon". It is of course especially preferred
that the cannula should comprise a medical-implant grade synthetic
polymer. In addition, it is also preferred that the hub should comprise a
biocompatible material suitable for use with drugs and next to skin.
Examples of such materials are polypropylene and polyurethane materials.
Furthermore, in the device of the invention the hub is preferably a
two-part hub-assembly, preferably with the separator means located between
the two parts of the hub. More preferably, in such a construction a first
hub-component comprises a body defining an axial bore which at its distal
end is adapted to receive the proximal end of the cannula, whereby the
through-passage of the cannula is positioned in communication with the
bore, and at its other end a socket communicating with the bore and
adapted to receive (mate with) a plug portion of a second hub-component,
also comprising a body defining an axial bore, the bores in the respective
first and second hub-components being aligned to communicate with each
other and together defining the through-passage in the hub assembly By
providing such a two-part construction, a self-sealing diaphragm can then
be sandwiched between the two hub-components e.g. between the distal end
of the plug-portion and the base of the socket.
Preferably, the first hub-component includes an elongated nose portion at
its distal end, within which a significant portion of the proximal end of
the cannula can be accommodated, thereby providing support for the cannula
and a means of securing the cannula to the hub, for example, by adhering
the outside of the cannula to the inside of the nose. Additionally or
alternatively, the bore in the first hub-component may be of greater
diameter than the diameter of the through-passage, where it accommodates
the tip of the proximal end of the cannula, thus providing an annular
abutment for the tip of the proximal end of the cannula, to permit
securing of the cannula to the hub.
In order to minimize pain during the initial injection through the
patient's skin, the cannula can advantageously be shaped at its distal tip
so that it tapers towards and close to the projecting tip of a
skin-puncture needle (when the latter is disposed within the device, to
enable it to penetrate the skin), and so that its front edges are
relatively smooth.
Also, while we have indicated above that the device may be taped in place,
other fixing means may be employed. Thus, for example, the hub of the
device may include a self-adhesive support portion to enable the hub to
adhere to the patient's skin when pressed thereagainst.
The device of this invention has been described above mainly in relation to
its use with insulin, but it is to be understood that its utility is not
necessarily confined to the administration of insulin but extends to the
administration of any therapeutic substance which requires the patient to
be injected (or above all to inject himself) frequently--say a number of
times in each day. Thus, for instance, the device can prove valuable in
the regular administration of morphine.
Furthermore, while the device has been primarily designed and therefore is
particularly suitable for self-administration on an intermittent basis, it
should be appreciated that it may also be used in conjunction with
apparatus for continuous administration. Thus, besides being useful in the
case where injections are given through the cannula as and when required
(either by means of a standard syringe or a cartridge device) the hub may
be adapted to be connected to means continuously to supply a therapeutic
substance such as insulin or morphine. Such means are currently available
and comprise a reservoir, a pump, a supply line and a needle for injection
purposes. Also, various kinds of sophisticated electronic means may be
included to achieve any necessary or desired control over the doses pumped
from the reservoir to the needle via the supply line.
For such use, the device preferably will include a hub having means to
provide or accommodate a supply line lock fitment. Thus, for example, the
hub may be formed with say one or more Luer lock lugs, or with means to
accommodate say a Luer lock adaptor.
Alternatively and preferably, the hub is of a two part hub-assembly as
described previously, and the hub components are arranged so that the
plug-portion of the second hub-component includes an annular flange, and
the plug-portion mates with the socket in the first hub-component in such
a manner that an annular locking groove is formed between the flange and
the end of the first hub-component adjacent the flange
Such an annular groove may be used to accommodate the front arms of a clip,
for example, a hinged clip like that described in co-pending British
Patent Application No. 85-17976 (Publication No. 2,161,709A) and European
Patent Application No. 85-30-5093.8 (Publication No. EP 0169704A). A said
clip may be defined as one having a body portion including at or adjacent
one end means, such as a pair of opposed depending arms, engageable with
the supply line or supply line connector, and at or adjacent its other end
a pair of opposed depending arms engageable with the groove, the said
means being arranged to permit the said arms engageable with the groove to
move into and out of engagement.
Preferably such a clip may be one for use with a supply line which includes
a pair of trunnion pins upstanding on either side of an end portion of the
line. The clip then may be formed with a first pair of opposed arms each
including an aperture so that they can be sprung over the trunnion pins
and the clip thereby pivotably mounted on the end portion of the line.
The invention also includes a device as defined and described herein in
combination with a skin puncture needle. Such a combination may be put up
for use packaged together with the needle disposed in the device in a
sterile pack. The pack preferably will include a self-sealing cap as
described herein to prevent ingress of dirt in use.
In addition, the invention includes a device as defined and described
herein in combination with a supply line arrangement. Preferably, in such
a combination the supply line arrangement includes mounted on an end
portion of the line a needle adapted to penetrate the separator means of
the device and a pivotal clip engageable with the hub of the device to
lock together the device and the supply line. More preferably, the hub may
be a two-part hub-assembly as described above with an annular locking
groove and the clip may be as defined above. Also, the supply line
arrangement may include a reservoir and/or a pump and/or electronic
control means as described above.
In order that the invention may be well understood a preferred embodiment
thereof will now be described in more detail, though only by way of
illustration, with reference to the accompanying drawings, in which:
FIG. 1 is a mainly cross-sectional view, taken in a plane through the axis,
of an embodiment of the device of the invention;
FIG. 2 is an essentially similar, mainly cross sectional view, of the
embodiment of FIG. 1, again taken in a plane through the axis of the
device, showing a cap-like closure member mounted thereon to prevent
ingress of dirt, and a skin-penetration needle fitted therethrough in its
operative, skin-penetrating position;
FIG. 3 is a non-sectional external view of the embodiment of FIG. 2, taken
in slight perspective from the distal end of the skin-penetration needle;
FIG. 4 is a mainly cross-sectional view of the same embodiment of the
device, generally similar to FIG. 2 but on an enlarged scale, and in which
the skin-penetration needle has been removed and replaced by the
hypodermic injection needle of a syringe;
FIG. 5 is a diagrammatic side view of a combination of a device in
accordance with the invention shown in unlocked association with a supply
line arrangement;
FIG. 5(a) shows the clip of FIG. 5 separate from the supply line
arrangement; and
FIG. 6 shows the combination of FIG. 5 locked together.
Referring to FIGS. 1 to 4 of the drawings, the device shown comprises a
cannula 1 having a delivery (through) passage or lumen 16. The cannula is
formed of biocompatible flexible synthetic plastics material and,
therefore, is capable of indwelling in a patient for a period of several
days after subcutaneous insertion thereof. The proximal end of the cannula
1 is mounted and secured (e.g. by adhesive) at the distal end of a
two-part hub assembly, generally indicated by the numeral 2, also formed
of a biocompatible but relatively rigid plastics material, and having a
through-passage 3 passing axially therethrough which communicates with the
delivery passage or lumen 16 within the cannula 1. The hub-assembly 2
comprises a first hub-component 4 and a second hub-component 5, each
having an axially-disposed bore therein which, in the assembled position
(as shown), is aligned with the axially-disposed bore in the other
hub-component, and which together constitute the through-passage 3. The
hub assembly 2 is formed by mating a cylindrical socket 6 in the proximal
end of the first hub-component 4 with a plug-portion 7 on the distal end
of the second hub-component 5. An annular collar 17 around hub-component 5
prevents the plug portion 7 from mating fully with the socket 6 in the
first hub-component 4 and, within the cylindrical chamber between the base
of the socket 6 and the end of the plug-portion 7, there is accommodated a
self-sealing diaphragm 8, formed of silicone rubber or another elastomeric
polymer. The diaphragm 8 is thus sandwiched between the hub-components 4
and 5, blocking communication between the axial bores therein and thus
normally sealing the through-passage 3. However, the diaphragm 8 may
easily be penetrated by a needle which is passed down the through-passage
3 to penetrate through the diaphragm.
In order to implant the indwelling cannula 1 subcutaneously in a patient,
in the manner which will be described in more detail hereinafter, a
skin-penetration needle 14 (see FIGS. 2 and 3) is passed through the
device down through-passage 3 until its tip protrudes beyond the distal
end of cannula 1. It will be seen that, in order to ease the implantation
of the cannula 1 subcutaneously into the patient, its distal end 1' is
externally tapered and fitted as closely as possible about the protruding
end of the skin-penetration needle 14.
The proximal end of the second hub-component 5 is provided with an
open-mouthed, conical indent generally designated by the numeral 9, whose
conical walls 9' are co-axial with and whose apex communicates with the
through-passage 3. As can best be appreciated from FIGS. 2 and 4, a
skin-penetration needle (FIG. 2) or a hypodermic injection needle (FIG. 4)
entering the device, is funnelled into alignment with the through passage
3 by this open-mouthed conical indent 9.
As appears from FIGS. 2 and 4, in order to prevent ingress of dirt or other
undesirable material into the open mouth of the conical indent 9 defined
by walls 9', a tubular-skirted cap generally indicated by the numeral 10,
and formed of elastomeric material, is removably fitted across the
otherwise open mouth of the conical indent 9. There it is held in position
by its depending tubular walls 11 adapted to embrace part of the
cylindrical outer surface of the main body portion of the second
hub-component 5.
As best appears from FIG. 4, in order the better to retain the cap 10 in
place and to ensure dirt-proof engagement between the tubular walls 11 of
the cap 10 and the outer surface of the main body-portion of the second
hub-component 5, the distal end of the latter, adjacent the plug portion
7, is provided with an annular groove 12, within which there is
accommodated a bulbous sealing ring 13 formed around the skirt-edges of
the tubular walls 11 of the cap 10.
In use, a skin-penetration needle 14 (see FIGS. 2 and 3) is passed through
the cap 10, funnelled by the conical indent 9 into the through-passage 3
and, after piercing the self-sealing diaphragm 8, enters and passes
through the lumen 16 of the cannula 1, until it extends somewhat beyond
the tapered distal end 1' thereof. With the skin-penetration needle thus
located, the cannula 1 the device is then subcutaneously implanted in the
patient, the hub-assembly 2 is taped or otherwise secured in place upon
the patient (e.g. his abdomen) and the skin-penetration needle is
withdrawn, leaving the device indwelling in the patient. There it may
remain for several days ready for intermittent or continuous use, as
required, for the administration (especially the self-administration) of
insulin, morphine or any other therapeutic substance.
Whenever it is appropriate to administer such a therapeutic substance, the
needle of the hypodermic injection syringe containing the substance is, as
shown in FIG. 4, passed in a similar manner through the cap 10. Again the
needle is funnelled by conical indent 9 into the through-passage 3, and
then pierces the self sealing diaphragm 8, but this time is there arrested
when the syringe-body 15 abuts against the cap 10. Thus, the hypodermic
injection syringe is placed in an ideal location adjacent the end of the
cannula 1 for the discharge of therapeutic substance from the syringe to
the patient through the device.
Referring to FIGS. 5, 5(a) and 6, the combination there shown comprises a
device 21 in accordance with the invention, for example, as described
above, and a supply line arrangement generally designated by the numeral
22. The supply line arrangement includes a supply line 23 e.g. a fine bore
line, through which a therapeutic substance such as insulin or morphine
may be fed e.g. by a pump arrangement, and an end portion 24. The end
portion 24 includes a needle 25 e.g. corresponding to the needle of the
syringe shown in FIG. 4, and a pair of trunnion pins 26 (only one shown).
Mounted on the end portion 24 via the trunnion pins 26 is a locking clip
generally designated by the numeral 27. The locking clip 27 comprises a
body portion 28 having a first pair of opposed depending arms 29
engageable with the trunnion pins 26 via through apertures 31 whereby the
clip 27 can be pivotably mounted on the end portion 24 as shown. The body
portion 28 also has a nose portion 32 and a second pair of opposed
depending arms 33 which are engageable with annular groove 12 (see also
FIG. 4) when the needle 25 is passed into the device 21 so that a
configuration of needle and device the same as or similar to that shown in
FIG. 4 is achieved.
Thus, the supply line arrangement 22 and the device 21 may be locked
together as shown in FIG. 6 so that the patient may receive a therapeutic
substance through the line 23. Thereafter, when treatment is complete the
combination may be unlocked by inserting a finger under nose portion 32
and lifting the arms 33 out of engagement with the annular groove 12, thus
releasing the device 21 from the supply line arrangement 22.
In the accompanying drawings to which the above description relates the
relative sizes of certain parts of the device are altered or exaggerated
for the purpose of clarity. However, it is to be understood that in
practice say the cannula end 1', the lumen 16 and the passage 3 will be
closely matched to the needle 14 e.g. as shown for the needle 14 and
passage 3 in FIG. 2.
As will be appreciated from the above description, the invention provides a
device in which accurate placement of the injecting or like needle can be
accomplished both in terms of alignment and in terms of penetration. In
particular, accurate placement in terms of alignment is achieved by
providing in accordance with the preferred embodiments described above a
hub defining a through-passage so constructed and arranged that the needle
is constrained by the diameter of at least part of the through-passage and
its alignment with the cannula lumen so that it must enter the lumen as it
passes through the self-sealing diaphragm or other separator means rather
than penetrate the cannula wall or otherwise be misaligned. Thus, the
respective cannula and hub through-passages being at least essentially the
same in diameter and at least essentially axially aligned lead to the
desired accurate placement.
While the invention is illustrated above by way of example with reference
to specific embodiments it is to be understood that the invention is not
limited to what is described. Thus, for example, the body of clip 27 may
be longer and arms 33 may engage the device 21 nearer its distal end e.g.
in another annular groove formed therein beyond groove 12. In that manner
the cap 10 may be left in situ in the combination of FIGS. 5 to 6.
Furthermore, as will be appreciated, other arrangements may be employed
and numerous variations may be made within the spirit of the invention
defined by the scope of the claims which follow.
* * * * *
|
|
|
|
|
Description  |
|